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1. Introduction 
Melanocytes are cells that originate in the neural crest. In the dermis, their well 
characterized role is to produce melanin and through interactions with keratinocytes 
transfer this pigment to determine skin color and protect the largest organ in the body, the 
skin, from ultraviolet light. As an effective free radical scavenger, melanin protects against 
reactive oxygen species that would otherwise damage DNA [Rózanowska et al., 1999]. 
Melanocytes may also have other roles such as immune, neuroendocrine, and signaling 
functions through interactions with cells other than keratinocytes, such as lymphocytes, 
mast cells and endothelial cells [see Tsatmali et al., 2002 for review]. However, keratinocytes 
regulate melanocyte number, differentiation and melanin production in response to UV 
radiation. It may be that the resilience of melanocytes to protect the skin, their extraordinary 
regenerative capacity and their origin as neural crest migratory cells makes them one of the 
most deadly forms of metastatic skin cancers when they undergo tumorogenesis. It is 
known that there is a great deal of common cellular and genetic events among embryonic 
development, tissue regeneration and cancer. Further, typical self-renewal and migration 
capacity of cancer are shared with embryonic and regenerative cells [White and Zon, 2008]. 
The recapitulation of embryonic genetic programs is facilitated by overexposure to extreme 
sunlight (UVA and UVB) or tanning bed light (mostly UVA). The American Cancer Society 
estimated that in the US in 2009, 68,720 new cases of melanoma (188 new cases /day) will be 
diagnosed and 8,650 people will die from the disease (24 melanoma deaths /day). The 
continued increase in melanoma is a significant cause of morbidity and mortality in the 
Western world. Thus, metastatic melanoma remains a persistent therapeutic challenge. There 
are limited successes in preventing this often fatal disease and there are even fewer successes 
in developing a cure. 
2. Standard melanoma therapies 
Presently available treatment strategies have had limited impact on progression and overall 
survival of patients with melanoma. In addition to surgery, currently approved treatments 
for metastatic melanoma include chemotherapy, radiation and/or immunotherapy. 
Chemotherapy is mostly limited to dacarbazine, cisplatin, carmustine and vinblastin. The 
addition of systemic immunotherapy with IL-2 and/or INFά to these chemotherapeutic 
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agents resulted in major toxicities. INFά is approved for use but is not included as a 
standard of care due to minimal impact on overall survival and significant toxicities 
[Amaravadi et al., 2007; Gogas et al., 2007; Tarhini et al., 2006]. Unfortunately, metastatic 
melanoma is one of the most resistant cancers to a wide range of treatment modalities 
including single-agents and combination chemotherapy, immunotherapy, 
chemoimmunotherapy and a host of immune stimulators [Riker et al., 2007].  
3. Targeted melanoma therapies  
One of the major problems that cancer therapeutics face today is coping with a diversity of 
cancer diseases and melanoma is no exception. However, Hanahan and Weinberg [2000, 
2011] reasoned that since all mammalian cells express the same molecular mechanisms for 
proliferation, differentiation and death, most if not all cancers should share a limited 
number of common molecular, biochemical and cellular traits that govern their behavior. 
This is insightful since cancers exhibit hundreds of genotypes and subtypes of tumors can be 
found in specific organs. In addition, different mutations can be found within the same tumor.  
In order to promote the development of cancer research into a more logical science, to 
provide more focused characterization of cancer and to manage this array of diseases, 
Hanahan and Weinberg [2000,2011] initially defined six major hallmarks of cancer that 
exhibit physiological anomalies that control cell homeostasis and proliferation. These 
include self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis. They later included reprogramming of energy metabolism 
and evasion of immune detection as cancer hallmarks [2011]. Kroemer and Pouyssegur 
[2007] included evasion of immune surveillance as a seventh hallmark. Luo et al. [7] 
expanded these classic hallmarks to include stress phenotypes of tumorigenesis and defined 
a large class of non-oncogenes that are essential for cancer cell survival. Treatment strategies 
to develop targeted, mutation-specific small molecule drugs or monoclonal antibodies to 
treat melanomas is an outcome of an evolving understanding of the molecular mechanisms 
of melanoma in the perspective of these defined cancer hallmarks.  
A number of new agents for advanced melanoma are being tested in clinical trials. 
Considering the hallmarks of cancer, the most recent new drugs for treating melanoma have 
found some successes in the inhibition of self sufficiency of growth signals, immune 
surveillance evasion, sustained angiogenesis and evasion of apoptosis. These agents are 
directed towards proteins that are involved in cell signaling pathways that are responsible 
for cell division and proliferation, immune responses, blood vessel formation and 
programmed cell death. Several considerations are appropriate when taking targeted drugs 
into account. First, targeted therapies are generally effective for individuals identified with a 
specific mutation, so patients can be screened before treatment to determine if they have the 
specific mutation for which the drug is designed to affect. This exemplifies the impact of 
personalized medicine on oncology and if successful will become a common procedure. This 
can be achieved by relatively simple and inexpensive procedures. The second concern is 
issues of heterogeneity within a patient’s melanoma. While a specific mutation may be 
determined in a biopsy sample, the targeted mutation may not be present in all of the 
patient’s melanoma cells. This provides a potential means for resistance and recurrences. A 
third issue is the continued “pressure” exerted or relieved by a targeted agent on cell 
signaling in the affected cancer cells. Such events modify signaling dynamics with responses 
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that attempt to “escape” the modification, which may also lead to resistance and 
recurrences. These issues may complicate uses of targeted medicine in melanoma 
treatments. 
Although other causes of cancer are known, mutations that often lead to malignant growth 
and metastasis frequently occur in protein kinases [Blume-Jensen and Hunter, 2001; Chenga 
and Force, 2010]. Protein tyrosine kinases transduce extracellular signals into intracellular 
functions that regulate a wide array of cellular activity. Tumorigenesis is often driven by 
constitutively active protein kinases that modulate cell cycle, angiogenesis or apoptosis. 
Two general classes of protein kinase inhibitors include monoclonal antibodies or small 
molecular weight inhibitors that are directed against specific protein tyrosine kinase 
receptors or their ligands. A common site for protein kinase inhibitor drug design is the ATP 
binding site because transfer of phosphate to substrates cannot occur without the gamma-
phosphate from ATP. However, the binding sites are so highly conserved among kinases 
that kinase genes can be identified without phosphotransferase activity by the presence of 
specific sequences that define ATP binding. Two major concerns in designing these drugs 
are issues of specificity and potency. Specificity is one issue because of the ATP binding site 
conservation among all protein kinases. Given the broad range of kinase functions, it 
becomes important to inhibit kinases involved in tumorigenesis without affecting other 
kinases. Potency is the other concern because ATP is at relative high concentrations in the 
cell (milliMolar) and an orally active small molecular weight drug must have a high affinity 
to be an effective inhibitor. Kinase inhibitors are divided into three major classes based on 
binding to their ATP site [Chenga and Force, 2010]. Type I inhibitors have high affinity for 
the ATP binding pocket. Therefore type I kinase inhibitors generally have broad kinase 
specificity. Type II kinase inhibitor (e.g., imatinib) are more selective because they not only 
have specificity for the ATP binding site but also sites adjacent the ATP binding site. In 
addition, unlike type I inhibitors, type II inhibitors can bind to kinases in their inactive 
conformation. Type III kinase inhibitors (e.g., families of mitogen-activated 
protein/extracellular signal-regulated kinase kinase inhibitors) are more selective but more 
difficult to design because they bind to sites distant from the ATP binding pocket. 
A number of monoclonal antibodies and targeted small molecular weight protein tyrosine 
kinase inhibitors are in clinical trials for the treatment of melanoma. Regarding the 
hallmarks of cancer, these agents are directed to prevent limitless replicative potential 
and/or self-sufficiency in growth signals, evasion of immune surveillance, sustained 
angiogenesis, and evasion of apoptosis. Because protein tyrosine kinases are involved in 
many of these hallmarks, many of these agents are multi-protein tyrosine kinase inhibitors 
that are directed towards more than one of these hallmarks and kinases so have overlapping 
targets. For example, Sunitinib, Sorafenib and Imatinib target VEGFRs and/or PDGFRs and 
can act as anti-angiogenesis agents. In addition, these drugs can also act on either c-Kit 
and/or Raf-1/B-Raf and are directed towards limitless replicative potential and/or self-
sufficiency in growth signals. Current data indicate that melanomas with activating c-KIT 
mutations and possibly also with KIT gene amplifications respond to therapy with tyrosine 
kinase inhibitors blocking c-KIT. It was suggested that subgroups of patients with metastatic 
melanoma prone to KIT mutations, such as primary mucosal and acrolentiginous 
melanomas, should be analyzed for their KIT status [Satzger et al., 2010]. 
A significant number of melanomas are mutated at V600E in BRAF (~60%), an oncogene 
that is a signal transduction enzyme near the origin or proximal end of a cascade of 
phosphorylation events that promotes proliferation through the Raf/Mek/Erk pathway and 
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survival of cells through the PI3K/Akt/mTor pathway. PLX4032, a B-raf kinase inhibitor 
has been shown to induce programmed cell death by inhibiting proliferation, growth and 
survival. It is also known to be involved in overcoming apoptosis evasion. In a recent multi-
phase phase I dose-escalation trial among 16 patients with melanoma exhibiting the V600E 
BRAF mutation, 62% (10 patients) had a partial response and 1 had a complete response 
when given PLX4032 (240mg or more twice daily). Among 32 patients in the extension 
cohort receiving as much as 960mg twice daily, 75% (24 patients) had a partial response and 
2 patients had a complete response. The estimated median progression-free survival among 
all patients was more than 7 months [Flaherty et al., 2010]. This represents an important new 
therapeutic development in the treatment of melanoma. For those who experienced 
relapses, second mutation(s) continue to drive tumorigenesis. Two mechanism of resistance 
to PLX4032 (covering 40% of cases) have been discovered. In one of these the cancer cells 
begin to overexpress a cell surface Beta-type protein platelet derived growth factor receptor 
creating an alternate survival pathway. In a second mechanism of resistance, the oncogene 
N-Ras mutates, reactivating the normal BRAF survival pathway [Nazarian et al., 2010].  
Several new agents have been evaluated for targeting the immune system. Several agonist 
monoclonal antibodies have shown promise including those directed against members of 
the tumor necrosis factor receptor superfamily such as 4-1BB (CD137), Ox40 (CD134), and 
CD40. Two human antagonists monoclonal antibodies have been investigated in melanoma 
patients that bind to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), which is a 
molecule on helper T-cells that appears to play an important role in regulating natural 
immune responses. These include Ipilimumab and Tremelimumab. Ipilimumab was 
recently evaluated alone and in combination with gp100 as compared with gp100 alone. In 
this phase III trial, it showed improved overall survival in patients with previously treated 
metastatic melanoma. Although there were some severe adverse reactions associated with 
this therapy they were reversible with appropriate treatment [Hodi et al., 2010; Peggs and 
Quezada, 2010]. Tremelimumab has been shown to induce durable tumor responses in 
patients with metastatic melanoma in Phase I and Phase II clinical studies [Reubens et al., 
2006] and more recently has shown promise in treatment of patients with metastatic 
melanoma, in a completed randomized, double-blind phase III trial [Callahan et al., 2010]. 
While most of the potential therapeutic agents are given orally, other delivery methods have 
begun to be used for more localized treatments and include the utilization of electric fields. 
One of these approaches is to maintain cell survival using conventional electroporation to 
deliver plasmids that express genes for therapeutic effects [Neumann et al., 2002]. This 
method is referred to as electrogene therapy. This is an outgrowth of electrochemotherapy 
that uses conventional electroporation to deliver impermeable chemotherapeutic drugs such 
as bleomycin to tumors [Heller et al., 1996; Mir et al., 1991]. The delivery of IL-12 to 
melanoma lesions to activate the immune system against melanoma by electrogene therapy 
has demonstrated safety and efficacy in phase I clinical trials. Results demonstrated a 
bystander effect where lesions surrounding electrogene-treated lesions showed tumor 
regression [Daud et al., 2008]. The use of electrogene therapy to deliver plasmids for gene 
expression in pre-clinical and clinical trials is reviewed elsewhere [Beebe et al., 2010].  
Two other therapies are based on uses of electric fields that extend conventional 
electroporation (EP). The first is irreversible electroporation (IRE), which extends EP by 
increasing the electric field to produce cell necrosis through irreversible plasma cell 
membrane defects [Al-Sakere et al., 2007; Davalos et al., 2005; Onik et al., 2007;], although 
some evidence suggests that ablation zones may also exhibit apoptotic cells [Guo et al., 2010; 
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Lee et al., 2010], a possibility that requires further investigation. IRE is also reported to affect 
only cell membranes and limits effects to cells within the ablation zone, sparing blood 
vessels, bile ducts and extracellular matrix structures [Maor et al., 2007; Phillips et al., 2010]. 
However, a major drawback is muscle contractions induced by microsecond pulses that are 
absent or significantly reduced with nanosecond pulses in a porcine model [Long et al., 
2011]. While IRE could be considered a blunt tool that forces cell death by necrosis (or 
apoptosis), it exhibits precision for applications because it can clearly define the intended 
treatment zone and spares larger vessels and ducts [Ivorra et al., 2009; Granot et al., 2009]. 
Another extension of conventional electroporation uses pulse power technology with 
nanosecond pulse electric fields (nsPEFs), which continues to be explored for tumor 
ablation. While there are some comparisons with conventional electroporation, pulse power 
is distinct in several regards. Compared to conventional electroporation, pulse power 
ablation (PPA) with nsPEFs uses exceptionally short pulse durations (ns vs. micro-second or 
milli-second) with exceptionally fast rise times (2-4ns vs. ~100ns). It is hypothesized that fast 
rise times with short pulse durations have advantages for intracellular effects [Schoenbach 
et al., 2001]. The electric fields used in these applications of pulse power are higher than 
conventional electroporation (10-350 kV/cm vs. about 1 kV/cm). Further, the power 
deposited in cells or tissues is much higher (~180MW vs. ~500W) and energy is lower 
(mJ/cc vs. J/cc); they are non-thermal. The combination of these conditions causes cell 
membrane supra-electroporation in all cellular membranes resulting in high density 
“nanopores” (nm diameter) [Gowrishankar et al., 2006; Stewart et al., 2004,]. 
4. Applications of ultra-high pulse power ablation for the treatment of 
melanoma 
Pulsed power is a technology designed to store energy and release it very quickly to produce 
immediate high power. It was initially developed during World War II for use in radar, which 
requires short high power pulses. Since then pulse power technology has been used in particle 
accelerators, ultra-strong magnetic fields, electromagnetics, fusion research and high power 
pulsed lasers. An example of how pulse power works is to compare the storage of one joule of 
energy released in one second versus releasing the same energy in one microsecond or one 
nanosecond [Wikipedia]. If the stored joule of energy is released all at once to a suspension of 
cells or tumor tissue in one second, the peak power delivered would only be 1 watt. If all of the 
stored energy were released within one microsecond, the power would be one megawatt, a 
million times greater and if release in one nanosecond the peak power would be one gigawatt, 
a billion times greater. Within the last ten years, applications of ultra-high pulse power have 
been extended to biology and medicine [Beebe et al., 2002, 2003a, 2004; Beebe and Schoenbach, 
2005; Schoenbach et al., 2001, 2004; Vernier et al., 2003a,b], including the treatment of 
melanoma [Chen, 2009, 2010; Ford et al., 2010; Nuccitelli et al., 2006, 2009, 2010]. In 
applications of pulse power ablation for treatment of melanoma, as much as 6 kV of potential 
energy were release in multiple 300ns bursts at 60kV/cm into murine B16f10 melanoma cells 
or tumors. In addition, the pulses included an extremely fast rise and fall time of about 4-5ns 
so the 300ns pulses were at maximum power for about 97% of each pulse. It is hypothesized, 
but not yet proven, that this rapid rise time is important for targeting intracellular organelles 
and may be an important aspect for therapeutic efficacy. 
Another factor that results from nsPEF conditions is the absence of significant temperature 
increases during treatment. Both in vitro and in vivo nsPEF studies have shown non-thermal 
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effects [Chen et al., 2009; Nuccitelli et al., 2006; Pakhomov et al., 2004;]. However, the 
presence or absence of thermal effects depends on the pulse repetition rate and heat 
dissipation rates of in vitro and in vivo systems. Higher frequency applications are more 
prone to thermal effects. While initial strategies for biological and medical applications were 
to achieve non-thermal effects, there may be advantages of synergistic effects between 
electric fields and heating. 
A combination of an ultrashort pulses and rapid rise times (shorter than the charging and 
relaxation time of plasma membranes), created conditions that were hypothesized and 
shown to have effects on permeabilization of intracellular granules in calcein-loaded human 
eosinophils without calcein release through the plasma membrane [Schoenbach et al., 2001]. 
Selective permeabilization of intracellular vesicles was also shown using a mixed population 
of phospholipid vesicles as well as in endosomal membrane vacuoles in COS-7 cells [Tekle 
et al., 2005]. Several other studies demonstrated effects that suggested selective 
permeabilization of intracellular calcium storage sites [Beebe et al., 2003b, 2004; Buescher 
and Schoenbach, 2003; Vernier et al., 2003a; White et al., 2004] and effects on plasma 
membranes that were unique compared to conventional electroporation pulses [Beebe et al., 
2003a; Deng et al., 2004; Ibey et al., 2010]. However, it was shown later that apparent 
absences of plasma membrane effects were likely due to formation of plasma membrane 
pores that were smaller than the reporter molecules, such as propidium iodide or ethidium 
homodimer [Bowman et al., 2010; Pakhomov et al., 2007a, b]. While these nsPEF 
applications are known to have effects on all cell membranes, differences among cell types 
and their sensitivities to pulse power conditions have been reported and will be discussed 
here.  
NsPEF effects have been observed on plasma membranes and intracellular membranes of 
the cytoskeletal structure, endoplasmic reticulum, mitochondria and nucleus. Many of these 
effects are hypothesized to be caused by the formation of “nanopores”, which occur during 
supra-electroporation [Gowrishankar et al., 2006; Stewart et al., 2004]. As stated earlier, this 
effect includes small pores on a large proportion of all cell membranes as opposed to larger 
pores on a small proportion of the cells membranes during conventional electroporation. 
However, this may need to be re-considered since more recent modeling approaches 
suggest that electroporation pulses generate fields inside cells that are high enough to 
permeabilize intracellular membranes and vesicles [Esser et al., 2010]. This paper predicts 
for EP that these membrane pores expand and become larger than nanopores arising from 
nsPEF. It will be important to experimentally test this in cells and tissues to discern real 
differences between conventional electroporation and nsPEFs concerning intracellular 
effects and therapeutic relevance. Nevertheless, nanopores allow small ion transport 
especially ions like sodium, calcium and potassium that can affect cell excitability. 
Conventional electroporation pores occur primarily in plasma membranes and allow 
transport of ions and larger molecules such as impermeable chemotherapeutic drugs and 
plasmids that express therapeutic genes. Like all dose related biological effects, the 
induction of nanopores has a threshold related to the pulse characteristics including 
duration, electric field and number. Thus, as pulse conditions increase to longer pulse 
durations, nanopores will begin to expand and assume characteristics of conventional 
electroporation. Thus, as pulse durations increase from very short durations to longer 
duration, there is a continuum from the presence of nanopores on all cell membranes to 
larger pores primarily on plasma membranes. Further, each cell type has different 
thresholds presumably based on cell membrane characteristics. 
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In addition to pulse duration alone, other pulse conditions such as pulse amplitude and 
pulse number can also influence cell behavior. Modeling results using molecular dynamics 
[Hu et al., 2006; Tieleman et al., 2003; Vernier et al., 2006] and continuum models [Joshi et 
al., 2001; 2002; Kotnic and Miklavcic, 2006; Smith et al., 2006] have provided insight into the 
mechanism of permeabilization of membranes with a single pulse. From an experimental 
point, Jurkat cells treated with 10ns and 60ns single pulses at various electric fields 
demonstrated an enhanced uptake of ethidium homodimer, a marker for membrane 
integrity, and an enhanced binding of Annexin V, a marker for phosphatidylserine 
externalization, both indicative of membrane permeabilization [Beebe et al., 2004]. In studies 
using Jurkat and U937 cells [Pakhomov et al., 2004] or GH3 and CHO cells [Ibey et al., 2009] 
under a variety of conditions, viability scaled with the absorbed dose as defined as the 
electrical energy density. Another study evaluating cell viability of murine B16f10 
melanoma cells with trypan blue using 0.8ns pulses seemed to confirm this [Schoenbach et 
al., 2008]. However these studies used different cell types and different pulse condition 
variables but did not include conditions of variable pulse durations, amplitudes and 
numbers together. When all three variables were included, the results scales with the 
product of the pulse duration (τ), pulse amplitude (E) and the square root of the pulse 
number (n0.5). This square root dependence on the pulse number indicates a statistical 
motion of cells between pulses with respect to the applied electric field, and can be 
explained using an extension of the random walk statistical results to random rotations of 
cells in solution [Schoenbach et al., 2009]. These studies can be of significant value to 
determine the underling interaction mechanism(s) between pulsed electric fields and cells 
and tissues. Collectively, these data suggest that there are multiple mechanisms of action of 
nsPEFs on biological systems. 
When effects of nsPEFs on cells are considered, it remains to be determined which effects 
are due to direct actions of electric fields on cell structure and function and which are due to 
secondary downstream cellular or biological effects that include responses from the 
cytoskeleton, endoplasmic reticulum, mitochondria, nucleus and DNA damage. Given 
conventional electroporation effects on cell membranes and now reports of nsPEF effects on 
all cell membranes including intracellular structures, it becomes difficult to determine which 
effects are direct and which are indirect. It seems clear that nanopore formation is a direct 
electric field effect, but it remains to be seen whether these nanopores are primarily 
responsible for initiation of all observed nsPEF effects, from specific structural effects to 
broadly based effects such as cell survival and cell death. It is possible that effects other than 
nanopore formation are present that may be unrelated to membrane charging events. 
However, there are presently no available published data to address this issue. While 
nanopores must have significant effects on cells, other downstream biological effects are still 
under investigation. Given that pulse power applications for the purposes of this review are 
for melanoma tumor ablation, we can ask how nanopores or other consequences of electric 
fields result in effects that we observe as melanoma cells die and melanoma tumors regress. 
Here we review literature that has led to understanding these effects from a number of cell 
types and then to recall some literature examples and present some data using nsPEFs on 
B16f10 melanoma cells and tumors. Given that pulse power using nanosecond pulsed 
electric fields can eliminate B16f10 tumors and prevent their return, we will focus on nsPEF 
effects that bear on hallmarks of cancer including reversing evasion of apoptosis and 
opposing sustained angiogenesis in tumors in vivo. However, both of these effects are 
related to a number of actions on cell membrane and organelles that lead to cell demise. 
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5. Effects of ultra-high pulse power on cell plasma membranes 
Although pulse power influences both plasma membranes and intracellular membranes, 
responses from the plasma membrane are relatively easy to analyze. It was initially 
hypothesized that pulse power fields could pass through the plasma membrane with 
significant effects. Using propidium iodide and ethidium homodimer as conventional 
probes for membrane permeability, initial studies suggested that our prediction was correct 
[Beebe et al., 2003; Schoenbach et al., 2001; Vernier et al., 2003]. However by using smaller 
fluorescent probes and more sensitive analytical methods, it has become clear that nsPEFs 
produce unique pores or aqueous channels that are distinct from conventional 
electroporation pores in that they are much smaller and are thus called nanopores. 
Pakhomov and coworkers have provided significant detail to the behavior of nanopores 
induced by nsPEFs [Bowman et al., 2010; Pakhomov et al., 2007a, b, 2009] but have only 
begun to fully characterize them. Pulses with durations of 60ns and electric fields of 12 
kV/cm showed long-lasting (minutes) reduction of the cell membrane resistance and a 
corresponding loss of the plasma membrane potential. The formation of nanopores was 
demonstrated by patch clamp analysis and verified by non-electrophysiological methods 
using Tl+-sensitive fluorophore and using Tl+ uptake as a marker for nanoporation. These 
nanopores are voltage sensitive, exhibit an inwardly rectifying current that resembles those 
of nonselective cation ion channels but do not appear to exhibit outward currents. These 
pore properties are distinct from conventional electro-pores, disappear when they become 
larger propidium permeable pores and are not blocked by broad-spectrum K+ channel 
inhibitors or Ca2+ chelators. Tl+ uptake was observed at electric field intensities far below 
the threshold for propidium iodide uptake and they remained stable for as long as ten 
minutes. Overall, nsPEF applications to cells in vitro provide evidence from models and 
experimental observations that they open lipid nanopores that create unique aqueous 
channels for cation-selective transport into cells from the extracellular environment. These 
plasma membrane nanopores are likely to be responsible, at least in part, for many nsPEF-
induced biological effects. Given that there is evidence for effects on intracellular 
membranes, it is highly likely that pulse power-induced nanopores are present in 
intracellular membranes and are responsible for at least some of the biological response 
from cells as will be discussed later. 
The plasma membrane separates cells from the external environment, but is much more 
than an external covering to contain intracellular organelles. This lipid bilayer includes a 
wide variety of integral membrane proteins that allow both passive and active transport of 
ions into and out of cells. In addition, the plasma membrane exhibits symmetry in lipid 
constituents on the inner and outer leaf of the membrane. Normally, phosphatidylserine is 
on the inner leaflet and phosphatidyl-ethanolamine is on the outer leaflet. During apoptosis, 
phosphatidylserine is externalized, signaling to other cells in the micro-environment that 
these cells are undergoing cell death by apoptosis. Under these conditions macrophages will 
engulf the dying cells by phagocytosis before cells lose their integrity through membrane 
permeabilization preventing inflammatory responses. However, since nsPEF conditions that 
lead to cell death will induce nanopore formation, cells may become permeable to 
membrane integrity markers such as propidium iodide or ethidium homodimer. Whether 
cell plasma membranes become permeable depends on EP conditions as discussed earlier. In 
addition, the cell type is also an important consideration as indicated in some of the 
following examples. 
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When ten 100ns pulses at 60kV/cm were applied to 3T3 pre-adipocytes and analyzed by 
flow cytometry, there was no increase in ethidium homodimer or propidium iodide uptake, 
indicating that the plasma membrane was impermeable to molecules on the order of about 1 
nm or larger. Using Annexin-V-FITC as a phosphatidylserine externalization marker, there 
was a time-dependent increase in Annexin-V binding but no increase in ethidium 
homodimer uptake 30 minutes after treatment [Beebe et al., 2003a]. Eighteen to twenty-four 
hours later less than 10% of the cells survived. These cells also exhibited active caspases, 
suggesting caspase-associated apoptosis.  
 
Fig. 1. Effect of nsPEFs on B16f10 melanoma cell permeability and phosphatidylserine 
orientation 
As indicated in Figure 1, B16f10 cells were also exposed to ten 300ns pulses with electric 
fields as high as 60 kV/cm. In contrast to 3T3 pre-adipocytes under these same conditions, 
there was very little if any Annexin-V binding indicating no phosphatidylserine 
externalization. However about 20-40% of cells took up propidium iodide at 60 kV/cm, 
suggesting that a minority of cells exhibited nanopores larger than about a nanometer. 
B16f10 cells also exhibited caspase activity (Ford et al., 2010, see below). Thus, 3T3-L1 pre-
adipocytes exhibited Annexin-V binding but no propidium iodide uptake while B16f10 cells 
exhibited no significant Annexin-V binding, but uptake of propidium iodide in a small 
population of cells. Both cell types showed increases in active caspases. When Jurkat cells 
were treated with nsPEFs, 300ns pulses at 60 kV/cm resulted in significant and immediate 
cell necrosis indicating that the plasma membranes of Jurkat cells were significantly more 
sensitive to pulse power than 3T3-L1 cells. Jurkat cells exposed to 60ns pulses at 60kV/cm 
exhibited Annexin-V binding but a delayed uptake of propidium [Beebe et al., 2003a]. The 
delayed permeability to propidium iodide was distinctly different than the immediate 
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propidium uptake when cells were exposed to 10 microsecond pulses typical of 
conventional electroporation [Deng et al., 2004]. When HCT116 cells that were wild-type 
and null for p53 were treated with nsPEFs, addition of ethidium homodimer-1 and 
Annexin-V-FITC post-pulse demonstrated greater fluorescence in p53 null cells versus p53 
wild-type cells, suggesting a p53-dependent biological effect on plasma membranes [Hall et 
al., 2005]. It is possible that relative levels of p53 may affect plasma membrane response to 
pulse power. 
The comparisons among these cell types demonstrates that different cells have unique 
responses to the same nsPEF conditions and that some cells respond to lower pulse 
conditions than others. The conclusion that there are cell-type specific responses to pulse 
power is consistent with several other studies [Hair et al., 2003; Ibey et al., 2010; Stacey et al., 
2003]. While these data indicate the possibility to selectively targeting specific cells in a 
mixed population, specificity for cancer versus normal cells has not been demonstrated. 
Nevertheless, it is highly likely that when electric fields are sufficiently high, pulse power is 
expected to eliminate all cell types, including slowly proliferating cancer stem cells, which 
are not readily affected by chemotherapeutic agents, and host cells that are collaborating 
with malignant cells. 
While propidium iodide uptake is a well-characterized marker for cell viability and 
phosphatidylserine externalization is a well characterized marker for apoptosis, both of 
these indicators and their indications should be reconsidered when cells are exposed to 
nsPEFs or conventional electroporation. It is well known from conventional electroporation 
studies that cells can be transiently permeable to relative large molecules and remain viable. 
The primary aim of conventional electroporation is transient membrane permeability in cells 
that survive. Transient permeability has also been demonstrated using nanosecond pulsed 
electric fields in HCT116 cells [Hall et al., 2007b]. It was hypothesized from modeling 
analysis [Hu et a., 2005, 2006; Vernier et al., 2006a, b] and demonstrated experimentally 
[Vernier et al., 2006] that exposure to nsPEFs could externalize phosphatidylserine through 
nanopores that were created in the plasma membrane. These nanopores are distinct from 
pores created by EP in that they are too small to allow transport of large molecules but do 
allow transport of ions and externalization of PS. Conventional electroporation induces 
phospholipid rearrangements in plasma membranes [Haest et al., 1997; Schwarz et al., 1999]. 
Tekle et al. [2008] demonstrate that phosphatidylserine externalization induced by nsPEFs in 
the absence of caspase activity, resulted in phagocytic clearance of B cells by mouse 
macrophages in part by electric field-induced apoptosis mimicry. Thus, analysis of 
phosphatidylserine externalization as an apoptosis marker in response to nsPEFs should be 
carefully considered and as always demonstration of apoptosis should include several 
different markers. 
It is also possible that nsPEFs have effects on other structures such as those with roles for 
transport across membranes or other biological effects. For example, ligand receptor 
interactions or the structure and function of membrane receptors could be affected by pulse 
power. Effects of pulse power have not been investigated on caveolae, which have been 
reported to play roles in endocytosis, lipid trafficking and signal transduction; and on lipid 
rafts, which have been implicated in cell signaling, membrane fluidity and protein and 
receptor trafficking [Brown and London, 1998]. Thus, while plasma membrane and putative 
intracellular membrane nanopores are likely important in biological responses to ultra-high 
pulse power effects on cells and tissues, other membrane structures and functions may also 
be modulated by pulse power. 
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6. Effect of nsPEFs on the endoplasmic reticulum 
The endoplasmic reticulum is composed of intracellular membranes with a similar 
composition to the plasma membrane, forming an intracellular network of tubules and 
cisternae or “little nets” (from the Latin reticulum). It carries out several specialized 
functions including translation, folding and transport of proteins, sequestration of calcium, 
glycogen storage, and responses to stress. Given that nsPEFs were hypothesized to have 
intracellular effects and these effects were most likely due to membrane charging events, it 
was reasonable to consider that they would have effects on this extensive intracellular 
membrane array. Since the endoplasmic reticulum is a storage site for calcium, a number of 
studies demonstrated effects of nsPEFs on calcium mobilization in the presence and absence 
of extracellular calcium [Beebe et al., 2003b, 2004; Buescher and Schoenbach, 2003; Vernier et 
al., 2003; White et al., 2004]. In fact, of all the cellular responses that have been elicited with 
nsPEFs, calcium mobilization is the one of the most sensitive, occurring at shorter pulse 
durations and lower electric fields than other measured cell responses. In experiments with 
HL-60 and Jurkat cells [Beebe et al., 2004; White et al., 2004] using 60ns pulses, calcium 
release was observed from intracellular storage sites in the absence or presence of 
extracellular calcium chelators at electric fields as low as 2-4kV/cm. Based on studies that 
depleted calcium stores in the endoplasmic reticulum, it was determined that calcium was 
mobilized from this site in these cells. For phosphatidylserine externalization in these same 
cells, 60ns pulses required electric fields 10-20 times higher (40 kV/cm). Calcium 
mobilization was also observed in Jurkat cells with ten 30ns pulses at 25kV/cm under 
conditions that did not allow Na+ transport across the plasma membrane [Vernier et al., 
2003]. NsPEFs also acted as an agonist to activate platelets to form platelet gels [Zhang et al., 
2008]. This effect was electric field dependent and was postulated to result from an increase 
in calcium mobilization through nanopores in the plasma membranes as well as from 
intracellular calcium stores, most likely alpha-granules in platelets. A study evaluating 
calcium responses in chromaffin cells exposed to nanosecond electric pulses suggested a 
role for L-type calcium channels for calcium entry, but not from intracellular calcium 
[Vernier et al., 2008]. A more recent study exposing chromaffin cells in the presence and 
absence of a variety of channel inhibitors concluded that 5ns pulses opened multiple types 
of voltage-gated calcium channels involving sodium transport across plasma membranes by 
either non-selective cation channels and/or lipid nanopores [Craviso et al., 2010]. Another 
study analyzed fluorescent calcium sensitive probes in isolated rat ventricular myocytes 
exposed to pulses of 4ns and electric fields at 10-80 kV/cm [Wang et al., 2009]. This study 
demonstrated that these ultrashort pulses triggered action potentials through tetrodotoxin-
insensitive, non-selective ion channels that were consistent with the presence of nanopores 
in the sarcolemmal. 
NsPEFs also mobilized calcium in B16f10 melanoma cells [Ford et al., 2010]. Calcium is 
involved in most, if not all cell functions [Berridge et al., 2000]. Mitochondria have a huge 
capacity to accumulate calcium and the permeability transition pore (PTP) complex is 
activated by calcium. When calcium levels markedly increase, the PTP complex can enter an 
irreversible high conduction state which dissipates the mitochondria membrane potential 
ultimately leading to cytochrome c release and initiation of apoptosis. We were interested to 
see if caspase activation was calcium-dependent. Chelators of calcium (EGTA and BAPTA) 
were used to prevent calcium effects and caspase activation was analyzed using the cell 
permeable, irreversible pan-caspase inhibitor, z-VAD-fmk. Ionomycin increased Ca2+ 3.1-
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fold and ten 300ns pulses at 60 kV/cm increased calcium nearly 2-fold using fluo-3 as a 
calcium indicator. Ionomycin, a calcium ionophore did not activate platelets above control 
levels. These same pulses increased the presence of active caspase by about two fold and 
increased the number of caspase positive cells from 20% in control cells to about 80% in 
nsPEF-treated cells. The presence of EGTA and BATA had no effect on the presence of active 
caspases.  
In a more recent study with E4 squamous carcinoma cells roles for calcium were more 
specifically identified [Ren and Beebe, 2011]. When conditions were sufficient to kill about 
95% of the E4 cell population (ten 300ns pulses at 60kV/cm), cytochrome c release and 
cleavage of the BH3 only protein Bid to t-Bid was only partially caspase-dependent. An 
analysis of effects of calcium on Bid cleavage using EGTA and BAPTA-AM to chelate extra- 
and intra-cellular calcium, respectively, determined that intracellular calcium as an intrinsic 
mechanism was responsible for about 30% of calcium-dependent Bid cleavage and 
extracellular calcium as an extrinsic mechanism was responsible for about 70% of calcium-
dependent Bid cleavage. This study also observed that nsPEFs activated calpains in a 
calcium-dependent manner, but experiments did not rule out involvement of other 
proteases. The results indicated that multiple mechanisms were involved in Bid cleavage 
and cytochrome c was released and calcium was mobilized from intracellular and 
extracellular sources. A possible common mechanism could be formation of nanopores in 
these membranes. 
There are other possible effects of nsPEFs on the endoplasmic reticulum. It is highly likely 
that other endoplasmic reticulum responses to pulse power will occur especially under 
conditions that are below the threshold or just above the threshold for cell death when a 
population of cells will not survive. This is especially relevant given roles for the 
endoplasmic reticulum in protein translation and folding. Cells respond to stress through 
changes in gene expression and the regulation of protein levels can be modulated by the 
endoplasmic reticulum. Regulation of eukaryotic initiation factor-2alpha by 
phosphorylation and internal ribosome initiation through the internal ribosome-entry site 
are two examples for direct roles of the endoplasmic reticulum in translation control in 
cellular stress responses and apoptosis [Holcik and Sonenberg, 2005]. Stress responses from 
the endoplasmic reticulum can also occur by crosstalk with the mitochondria to induce 
cytochrome c release or through caspase-12, which is transported to and/or located in the 
mitochondria and can act without cytochrome c release [Momoi, 2004; Szegezdi et al., 2003]. 
Under these conditions, the downstream responses of endoplasmic reticulum stress include 
a mitochondria-mediated response, often involving calcium mobilization or a mitochondria-
independent response that involves the activation of caspase-12 and caspase-4. Both of these 
“pathways” lead to the activation of executioner caspases. Effects of nsPEFs in the stress 
response, control of translation and caspase activation through effects on the endoplasmic 
reticulum have not been investigated. 
7. Effect of nsPEFs on mitochondria 
Mitochondria are often referred to as the cell’s “power plant” since they are responsible for 
production of ATP. However, another important function of mitochondria is in 
programmed cell death. A primary focus here will be on the role of mitochondria in pulse 
power-induced cell death, which will be discussed with specific references to effects on ATP 
levels, mitochondria membrane potential and release of pro-apoptotic factors. Analyses of 
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nsPEF effects on mitochondria have only just begun by analysis in B16f10 melanoma [Ford 
et al., 2010] as well as E4 squamous cell carcinoma [Ren and Beebe, 2011]. Ford and co-
workers [2010] recently demonstrated that nsPEFs induced a decrease in cellular ATP levels 
and decreased the mitochondria membrane potential in B16f10 melanoma cells. The loss of 
the mitochondria membrane potential is a common event during apoptosis. Figure 2 shows 
effects of nsPEFs on the mitochondria membrane potential in B16f10 melanoma cells.  
 
 
Fig. 2. NsPEFs decreases the mitochondria membrane potential in B16f10 cells. 
In non-apoptotic cells, JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine 
iodide) exists as a monomer in the cytosol as a FITC fluorophore as shown through the 
green channel on the X-axis. It also accumulates as aggregates in the mitochondria which 
stain red as shown through the PE-Texas Red channel on the Y-axis. In apoptotic and 
necrotic cells, aggregated, red JC-1 decreases and monomeric, green JC-1 increases. The top 
left panel of Figure 2 shows control cells in two populations with different green monomeric 
JC-1 intensities. As nsPEFs are applied to the cells with increasing electric fields, red JC-1 
aggregate intensities decrease (Y-axis) and green JC-1 monomer intensities increase (X-axis). 
The decrease in the mitochondria membrane potential occurred as quickly as it could be 
measure by flow cytometry (minutes). This transformation occurs in an electric field-
dependent manner indicating that electric fields caused a decrease in the mitochondria 
membrane potential. As expected, the levels of ATP drop significantly in a similar manner 
[Ford et al., 2010]. Given that nsPEFs cause nanopore formation in the plasma membrane 
and also have effects on intracellular membranes it is possible that the electric fields cause 
nanopore formation in the inner mitochondria membrane resulting in a decrease in the 
potential across the membrane. Another possibility is that nanopore formation in the plasma 
membrane causes an increase in sodium in the cytosol, which causes the decrease in the 
mitochondria membrane potential. Further experimentation will be required to differentiate 
between these two possibilities. 
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Another common event during apoptosis is the release of pro-apoptotic factors from the 
mitochondria. Several methods are available to analyze cytochrome c release including 
immunoblots using mitochondrial-free cytosolic fractions [Beebe et al., 2003a]. Using this 
assay it is more difficult to quantify cytochrome c release and it is not possible to determine 
the number of cells in a population that release cytochrome c. Another approach is to use 
fluorescent antibody detection of cytochrome c by fluorescent microscopy and/or flow 
cytometry.  
Cytochrome c release using immunoblot analysis was demonstrated in Jurkat cells exposed 
to nsPEFs [Beebe et al., 2003a]. Cytochrome c release occurred within 30-45 minutes after 
treatment and was coincident with caspase activation, which was determined with the cell 
permeable irreversible inhibitor z-VAD-fmk. NsPEFs also initiated cytochrome c release in 
HCT116 colon carcinoma cells, albeit it did not occur until the second hour, which was after 
active caspases were present. In B16f10 melanoma cells cytochrome c release was analyzed 
as well as release of the pro-apoptotic factors Smac/Diablo and apoptosis initiating factor 
(AIF). These results are shown in Figure 3 (below). 
Unlike all other cells tested for cytochrome c release in response to nsPEFs, and in contrast 
to ethanol treated cells, B16f10 cells did not release cytochrome c while active caspases 
were detected using z-VAD-fmk [Ford et al., 2010]. Cells in experiments shown in Figure 
3 were analyzed 3 hours after treatment. However, when analyzed between 1 and 7 hours 
after treatment, cytochrome c released was not detected. In data not shown, a second 
assay was used that was based on a loss of cytosolic cytochrome c from permeabilized 
cells before analysis with fluorescent antibodies (Innocyte assay, Cal Biochem) based on 
the procedure described by Waterhouse and Trapani [2003]. We were unable to detect 
cytochrome c release using this assay while about 50% of E4 squamous carcinoma cells 
released cytochrome c 1 hour after treatment with nsPEFs [Ren and Beebe, 2011]. 
However, as indicated in Figure 3, we did detect small increases in fluorescence with 
antibodies to Smac/Diablo and apoptosis initiating factor (AIF), albeit in small 
populations of cells (10-15%). Given that cytochrome c release was detected in Jurkat cells 
coincident with activation of caspases (Beebe et al., 2003a] as well as in HCT 116 cells 
[Hall et al., 2007a] and E4 squamous carcinoma cells [Ren and Beebe, 2011] after caspase 
activation, this suggests that nsPEFs have cell type-specific effects on mitochondria-
mediated events associated with apoptosis-like mechanisms.  
8. Effects of nsPEFs on nucleus / DNA 
Possible effects of nsPEFs on the nucleus have been of specific interest since the technology 
was applied to cells and tissues. Given that these effects on cells and tissues are high in 
power and low in energy density, it would be expected that the energy deposited into cells 
from these electric fields would not be sufficient to break hydrogen bonds, especially those 
in DNA. However, some experimental data suggests that this might not be true in cells in 
vitro and tumor tissues in vivo. Fibrosarcoma tumors grown in mice and treated with nsPEFs 
ex vivo exhibited DNA damage using TUNEL analysis [Beebe et al., 2002, 2003b]. Stacey and 
colleagues [2003] evaluated possible genotoxic stress effects of ultra-high pulse power using 
nanosecond pulsed electric fields on 11 suspension and adherent cell lines. They evaluated 
cell survival assessed by clonogenic formation or live cell counts; DNA damage was 
determined by the comet assay and chromosome aberrations and cell cycle parameters by 
measuring the mitotic indices of exposed cells. Not all cell types were affected in the same 
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Fig. 3. NsPEFs have minimal effects on release of pro-apoptotic factors from mitochondria in 
B16f10 melanoma cells. 
ways. After one 60 ns pulse with an electric field intensity of 60 kV/cm, non-adherent 
cultures exhibited a rapid decline in cell viability (90%), DNA damage, and a reduction in 
the number of cells reaching mitosis. Adherent cultures did not exhibit these effects under 
the same conditions with the exception of mouse 3T3 cells, which behaved as the suspended 
cells did. These results suggested that pulse-power-induced genotoxicity may be cell type-
specific and therefore have possible applications in the selective removal of one cell type 
within a heterogeneous population of cells such as in diseased states. The comet assay also 
suggested possibilities for DNA damage in B16 cells in vitro when treated with nanosecond 
pulsed electric fields [Nuccitelli et al., 2009].  
Another approach to identify effects on DNA was to use phosphorylation of Histone 2AX to 
identify possible DNA double strand breaks using fluorescent antibodies by flow cytometry 
or fluorescent microscopy. When DNA double strand breaks occur, Histone 2AX, a histone 
variant, is phosphorylated on Serine 139 and serves as a sensitive and early monitor to 
identify these events [Bonner et al., 2008; Rogakou et al., 1999]. When B16f10 cells were 
exposed to 300ns pulses at 60kV/cm, it was not possible to determine an increased Histone 
2AX phosphorylation. While there were significant levels of phosphorylated Histone2AX, 
there were no significant differences between control and treated cells, even though >95% of 
treated cells were eliminated 24 hours later [Ford et al., 2010]. This suggests that DNA 
double strands breaks are not uncommon in control B16f10 cells. However, results were 
different in HCT116 cells. 
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Fig. 4. NsPEFs induce DNA double strand breaks in HCT 116 colon carcinoma cells. 
HCT116 colon carcinoma cells were exposed to ten 300ns pulses at various electric fields and 
analyzed for Histone 2AX phosphorylation with fluorescent antibodies specific for 
phosphorylation at the serine 139 site. Figure 4 (above) shows identification of 
phosphorylated Histone 2AX in HCT116 cells treated with ten 300ns pulses at 40 or 60 
kV/cm. The top panels show 20x magnifications of cells treated with 60kV/cm, a condition 
that resulted in death of >95% of cells. Within 5-10 minutes HCT116 cells were positive for 
phosphorylation of Histone 2AX. The bottom panels shows 60x oil magnifications of 
representative HCT116 cell nuclei that were phosphorylated at Serine 139. The rapidity of 
phosphorylation was surprising if nsPEFs did not have direct effects on DNA. A common 
mechanism for DNA damage in response to ionizing radiation is the generation of reactive 
oxygen species. However, we were unable to detect reactive oxygen species in B16f10 cells 
treated in the same way [Ford et al. 2010]. These results were consistent with results of DNA 
damage using the comet assay, which identified rapid DNA damage [Stacey et al., 2004; 
Nuccitelli et al, 2009]. In experiments analyzing nsPEF effects on DNA double strand breaks 
in Jurkat cells that resulted in >95% cell death, Histone 2AX phosphorylation occurred 
several hours after treatment and was caspase-dependent, suggesting that this DNA 
damage was due to apoptosis [Ren and Beebe, unpublished results]. Taking all of this data 
together, it appears that nsPEF-induced DNA damage is cell type specific.  
More general nsPEF effects on cell nuclei in HL-60 cells were determined in cells when non-
lethal pulse power conditions caused the nucleus in acridine orange-stained HL-60 cells to 
become irregularly shaped as the fluorescence decreased [Chen et al., 2004]. When HCT116 
cells were treated with non-lethal pulse power using nanosecond pulsed electric fields, 
reversible changes in nuclear size and morphology were observed indicating effects on 
nuclei even under conditions that resulted in cell survival [Hall et al., 2005]. In a different 
approach to analyze nsPEF effects on cell nuclei, Chen and co-workers [2007] used confocal 
microscopy and flow cytometry to observe Smith antigen antibody (Y12) binding to nuclear 
speckles, known as small nuclear ribonucleoprotein particles (snRNPs) or intrachromatin 
granule clusters (IGCs), in Jurkat cells following one or five non-lethal 10ns pulses at 150 
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kV/cm. These experiments indicated that nsPEFs disrupted pre-messenger RNA splicing 
mechanisms but did not allow propidium uptake, suggesting the nuclear effects occurred in 
the absence of plasma membrane pores larger than about a nanometer. Furthermore, these 
effects were cell cycle dependent. When cells were synchronized to the G2-M phase with 
nocodazole, exposing cells in the mitotic phase to five consecutive 10ns pulses immediately 
and significantly increased the number of nuclear speckled substructures, suggesting direct 
effects to inhibit RNA transcription mechanisms. While these pulse power conditions 
resulted in significant cell survival, the long term effects after these responses have not been 
analyzed. 
NsPEF effects reviewed thus far have been with B16f10 cells and other cell types in vitro. 
Effects on DNA in B16f10 tumors in mice have been analyzed [Chen et al., 2010]. In these 
studies, hairless female SKH-1 mice were injected subcutaneously with 1x106 B16-F10 cells. 
Tumors developed within 8-10 days. B16f10 tumors were treated in vivo with one hundred 
300ns pulses at 40kV/cm and analyzed for phosphorylated Histone 2AX, 1, 3, 6 and 24 
hours after treatment. The results indicated a time-dependent increase in ǄH2AX in 
melanoma, with significant differences occurring at 1 hour (15% of cells), reaching a peak at 
3 hours (85% of cells) and decreasing to control levels thereafter. These transient peaks in 
Histone 2AX phosphorylation coincided with TUNEL positive cells and pyknotic nuclei. 
Quantitative differences were observed by calculating mean nuclear area (μm2) between 
control and treated tumor nuclei during the first 24 hours after treatment with nsPEFs. 
Treated tumor nuclei were significantly smaller than control nuclei. The transient nature of 
histone 2AX phosphorylation and TUNEL positive cells suggested that DNA repair was 
initiated but not completed. When DNA was analyzed by agarose gel electrophoresis large 
DNA fragments, but not 180bp fragmentation ladders, were observed. The presence of 
active caspases peaked after peaks of histone 2AX phosphorylation and TUNEL positive 
cells. Taken together, these results suggested that the DNA damage occurred by a caspase-
independent mechanisms and that apoptosis did not go to completion (see nsPEF effects on 
apoptosis mechanisms, below). 
Most data for effects of pulse power-induced effects on DNA in cells and tissues suggests 
that at least some DNA damage may be caused by direct nsPEF effects. DNA damage in 
B16f10 melanoma cells and tumors does not appear to be a caspase-associated apoptosis 
marker. However, the mechanism(s) remain to be defined. Pulse power is not expected to 
generate sufficient energy to break hydrogen bonds and it may not be expected to generate 
reactive oxygen species through ionization of water. However, reactive oxygen species can 
be generated by effects on mitochondria, which are clearly present after pulse power 
treatment of B16f10 and other cells. Nevertheless, pulse-power induced reactive oxygen 
species in B16f10 cells [Ford et al., 2010] or E4 squamous carcinoma cells [Ren and Beebe, 
2011] in vitro were not detected when CM-H2DCFDA was used as a reactive oxygen species 
marker. Since ATM (ataxia telangiectasia mutated) kinase and/or ATR (ATM and Rad 3-
related) kinase are activated with ionizing radiation and UV light, it would be of interest to 
carry out kinetic analysis of these kinases after cells are exposed to pulse power and 
correlate this with histone 2AX phosphorylation. 
9. Effect of nsPEFs on actin cytoskeleton 
The cytoskeleton forms a dynamic network of filamentous protein structures that 
crisscrosses the cytoplasm, providing shape, mechanical support, modes for intracellular 
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transport of synthesized proteins and the capacity for motility. It is contiguous with the 
plasma membrane. Given that nsPEFs have effects on plasma membranes and intracellular 
structures and the cytoskeleton is an extension of the plasma membrane, it was likely that 
nanosecond pulsed electric fields would affect the cytoskeleton. 
Effects of pulse power ablation on the actin cytoskeleton have been demonstrated [Hall et 
al., 2007a]. Human HCT 116 colon carcinoma cells were synchronized to S phase (95%) by 
thymidine block or analyzed unsynchronized (50% S phase). The actin cytoskeleton was 
labeled with rhodamine phalloidin and pulsed with three 60ns pulses at 60kV/cm and 
visualized by fluorescent microscopy. Both S-phase synchronized and unsynchronized 
control cells exhibited well-defined peripheral cytoskeletal structures around large nuclei. 
One hour after treatment, the cytoskeletal structure of unsynchronized cells exhibited a 
more random, less organized structure near the plasma membrane with blebbed-like 
structures. In contrast, the cytoskeletal structure of S phase cells exposed to the same pulses 
was not significantly perturbed. Five hours after treatment with these conditions, control 
and treated cell were indistinguishable with 90-95% survival [Hall et al., 2007a]. When these 
cells were pulsed with three 300ns pulses at 60kV/cm, which killed 90% of cells, S-phase 
cells and unsynchronized cells exhibited rearranged actin cytoskeletons. 
These experiments demonstrated several new facts about nsPEF effects on actin and how actin 
functions in HCT 116 cells. First, nsPEFs have differential cytoskeletal effects on cells in S 
phase, but no differential effects on survival. A second aspect is the capacity of the actin 
cytoskeleton to resist effects of nsPEFs during DNA synthesis. This is contrary to the idea that 
proliferating cells, with potentially vulnerable DNA in the absence a nuclear membrane, 
would be more susceptible to nsPEFs. Third, when nsPEFs perturb the actin structure with low 
level pulse power (three 60kV/cm pulses at 60 or 300ns), there is a transient influence that 
allows recovery between 1 and 5 hours after treatment with cell survival. However, when 
pulse power conditions are sufficiently intense, cells cannot survive the exposure. In these 
studies, two nsPEF thresholds are demonstrated. One threshold is for pulse power intensity 
that supersedes the capacity of actin cytoskeleton to resist rearrangement during DNA 
synthesis in S-phase and a second threshold is pulse power intensity that surpasses the 
capability of cells to survive nsPEF ablation. This suggests that in some tumors this treatment 
could complement chemotherapeutic agents such as vincristine, vinblastine and other vinca 
alkaloids that bind to tubulin and prevent polymerization as well as paclitaxel and other 
taxanes that bind to tubulin and prevent depolymerization. 
Effects of nsPEFs on B16f10 cell actin cytoskeletal structures using ten 300ns pulses at 
60kV/cm, like that used in HCT 116 cells had unnoticeable effects on the cytoskeleton [JA Liu 
and SJ Beebe, unpublished]. This again suggests cell type-specific differences. This may not be 
too surprising since pulse power-induced plasma membrane effects were different between 
B16f10 and HCT116 cells as well as other cells. However, Ford et al. [2010] observed that when 
active caspases were expressed in B16f10 cells, the actin cytoskeleton was not readily observed 
2-3 hours after pulse power treatment. Since actin is a caspase substrate, this suggested that the 
actin cytoskeleton is dismantled by active caspases after pulse power treatment. 
10. Effect of pulse power on apoptosis-like cell death mechanisms 
The landscape for defining cell death mechanisms has become more complex as our 
understanding of life and death advances. Since apoptosis initiation and progression are 
complex processes and are cell type-specific, apoptosis mechanisms and pathways are often 
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simplified by classifying pathways as intrinsic and extrinsic. The extrinsic pathways is 
further classified as type I cells that do not use mitochondria cytochrome c release and type 
II cells that do [Fulda and Debatin, 2006; Lavrik, 2010]. The fate of cells depends on a set of 
sensors and positive and negative regulators whose balance will determine cell fate and 
whether apoptosis is initiated or not. The mitochondria play major roles in these 
mechanisms. There may be no linear apoptosis pathways, but grouping apoptosis into 
intrinsic mechanisms, which are linked to the mitochondria, and extrinsic mechanisms, 
which are linked to death receptor complexes in the plasma membrane, provides some 
structure for discussion and analysis. There also appears to be an intrinsic mechanism that 
originates in the endoplasmic reticulum and may or may not be linked to the mitochondria. 
The intrinsic pathway is regulated through pro- and anti-apoptotic Bcl-2 family members in 
response to intracellular stresses with mitochondria-dependent release of cytochrome c and 
other factors causing activation of apical initiator caspase-9 through formation of the 
apoptosome with APAF-1. This then leads to activation of downstream execution caspases -
3, -6, and/or -7. The regulation of mitochondria-dependent mechanisms is complex. 
Activators of this pathway include endoplasmic reticulum stress, as discussed earlier, DNA 
damage, hypoxia, and reactive oxygen species and growth factor deprivation, among others. 
Caspase activation is controlled by inhibitors of apoptosis (IAP), which can be inactivated 
by pro-apoptotic factors released from the mitochondria such as Smac/Diablo and 
Omi/OtrA. P53, the “guardian of the genome” senses potential apoptotic signals and leads 
to increases in factors such as Puma, Nova, and Bax, which lead to release of cytochrome c. 
However, these factors are opposed by anti-apoptotic factors such as Bcl-2 and Bcl-xl. 
The extrinsic pathway is initiated by death receptor ligands that bind and trimerize death 
receptors such as Fas, TNF or TRAIL at the plasma membrane. This signals the recruitment 
of intracellular adaptor proteins and the apical initiator caspase-8 to the plasma membrane 
and the formation of a death-induced signaling complex (DISC). In type I cells, caspase-8 
directly activates the executioner caspase-3. The formation of DISC is also regulated by 
positive (caspase-8) and negative (FLIP) regulators. In some cells (type II), formation of the 
DISC is insufficient to signal caspase-8 and caspase-3 directly. Instead caspase-8 cleaves a 
BH-3 only Bcl-2 pro-apoptotic protein Bid, forming a truncated Bid (t-Bid) that signals 
through the mitochondria, releasing cytochrome c causing activation of caspase-9, like that 
occurring in the intrinsic mechanism. In this way, the extrinsic pathway is connected to the 
intrinsic pathway through mitochondria-mediated mechanisms in type II cells. 
Mechanisms for nsPEF-induced apoptosis induction appear to be dependent on the pulse 
conditions and/or on cell type. For example, pulse power-induced Jurkat cell apoptosis, in 
response to three 60ns 60kV/cm pulses, involved coincident release of cytochrome c and 
activation of caspases within the first 30-45 minutes after pulse delivery [Beebe et al., 2003a]. 
However, it is not yet clear if this mitochondria-dependent response occurs through the 
intrinsic pathway due to intracellular effects on the endoplasmic reticulum or mitochondria 
or occurs through the type II cell extrinsic pathway. In contrast, nsPEF-induced apoptosis in 
HCT116 colon carcinoma cells involves caspase activation in the first 45-60 minutes post-
pulse with cytochrome c release as a later event [Hall et al., 2007a]. 
When B16f10 cells were suspended in Dulbecco’s PBS (DPBS) solution and exposed to ten 
300ns pulses with increasing electric fields, an increasing number of cells exhibit active 
caspases as determined 1 hour after treatment using the cell permeable pan caspase 
irreversible inhibitor z-VAD-fmk [Ford et al., 2010]. This is opposed to elevating caspase 
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levels in a given population of cells. Thus this increase in the numbers of cells with active 
caspases occurred in an electric field-dependent increments. About 10% of cells were 
positive for active caspases in untreated cells and that number increased to greater than 75% 
when treated with ten 300ns pulses at 60 kV/cm. The analysis by flow cytometry indicated 
an increasing population of cells shifting to the right with increased fluorescence with the 
FITC- labeled pan caspase probe. This indicates that cells become positive for this probe in 
an all or none manner. This is consistent with the concept that once caspases are active they 
reach a point-of-no-return with a positively reinforced cascade of caspase activation leading 
to cell death. In addition, this behavior indicates that the B16f10 cell population responded 
in a heterogeneous manner with only a subpopulation of cells showing positive responses 
with each increasing electric field increment. Also when cells were treated with 20% ethanol 
they become positive for active caspases. 
In another experimental approach, cells were treated as in Figure 5 with ten 300ns pulses at 
60 kV/cm and analyzed by fluorescent microscopy. DAPI was used to identify the nuclei 
and a cell permeable, irreversible inhibitor or pseudosubstrate (Sulforhodamine-DEVD-fmk 
with red fluorescence) was used to identify caspase-3/7 (Figure 5). In controls that were 
sham treated without exposure to electric fields (0 kV/cm), cell nuclei were stained blue 
with DAPI, but caspase-3/7 cells were essentially absent {or in few cells (<10%)} and 
therefore exhibited little of no red fluorescence. Cells that were treated with nsPEFs ultra-
high pulse power as indicated above exhibited a large population of red fluorescence with 
the presence of active caspase-3/7. 
 
 
Fig. 5. nsPEF treated b16f10 cells exhibit increased binding of a cell permeable, irreversible 
caspase inhibitor. 
Based on available evidence, it appears that nsPEF-induced apoptosis in B16f10 cells mimics 
the extrinsic pathway because active caspase-3-7 were present without concomitant 
cytochrome c release from B16f10 cells. Thus, pulse power induced apoptosis in these cells 
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by mechanism(s) that were mitochondria-independent. Of interest here it the possibility for 
these pulses to activate mechanisms that bypass mutations that are common in cancer and 
resistances to treatment through mutations in mitochondria-mediated apoptosis 
mechanisms. For example [see Soengas and Lowe, 2003 for a review], Bcl-2 is often 
upregulated in melanoma to protect cells from apoptosis by inhibiting cytochrome c release 
from mitochondria. In addition, MitF is a factor that may also contribute to melanocyte 
survival by the transactivation of Bcl-2, which supports melanocyte survival. In addition, 
Apaf-1 protein and mRNA expression are frequently downregulated in metastatic cell lines 
and tumor specimens. Neither of these mutations would deter nsPEFs from preventing 
melanoma ablation. Thus, there may be advantages for applying pulse power ablation for 
eliminating melanoma at early stages (see below). 
11. Multiple mechanisms for nsPEFs to eliminate cancer cells in vitro 
Effects of nsPEF conditions have been observed that are coincident with a number of cellular 
responses from plasma membranes, intracellular cell membrane, proteases, and Bcl-2 family 
member proteins. Cell responses that seem to happen rapidly are likely direct actions of 
membrane charging and/or energy density “dose” effects are decreases in the plasma cell 
membrane potential as well as the mitochondria membrane potential. Phosphatidylserine 
externalization can also occur as a direct effect of pulse power. The best explanations for 
these phenomena are the formation of nanopores in those membranes. Likewise, increases 
in intracellular calcium occur by mobilization from extracellular and intracellular sources, 
which are relatively rapid and sensitive responses that could also be due to nanopores in the 
plasma membrane and endoplasmic reticulum. Other pulse-power-induced cellular 
responses include cytochrome c release, cytoskeletal changes, disruption of pre-messenger 
RNA splicing mechanisms, changes in nuclear shape and morphology, DNA double 
stranded breaks and general DNA damage, depending on pulse power conditions and the 
cell type. Other changes include increases in active caspases and calpains, cleavage of Bid to 
t-Bid and changes in other Bcl-2 proteins. There appears to be different thresholds and some 
of these changes appear to be dependent on the cell type. Under intense pulse power 
conditions, cells die by different mechanisms that may or may not be related to 
programmed cell death such as apoptosis and other death responses may be due to caspase-
independent mechanisms including necrosis. Since many of these responses have been 
observed in different cell types, under different pulse power conditions and cell 
concentrations, in different buffers and by different assay procedures, it is difficult to 
determine specific cell death mechanisms. Just as difficult to determine is whether cell death 
is due to direct electric field effects or subsequent biological effects and whether cell death 
or sub-lethal effects are due to plasma membrane or intracellular membrane charging or 
energy density-related effects. Based on our present understanding of these numerous 
complex events, it is safe to conclude that given the plethora of cell responses that cell death 
is due to multiple mechanisms that depend on a variety of conditions. Given these complex 
scenarios, it could be simply proposed that when pulse durations are short and electric 
fields are low a minimal number of cellular “targets” respond. As the pulse durations 
become longer and electric fields higher, increasing numbers of “targets”respond. Where 
these targets are located and how sensitive they are or what their thresholds are appears to 
be dependent on the cell type. 
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12. Multiple mechanisms for nsPEFs to eliminate tumors in vivo 
Treatment of melanoma requires new modalities to those presently available. Presently 
available melanoma therapy has significant limitations due to poor efficacy, quasi-tolerable 
toxicity and limited enhancement in survival and life quality. Here we discuss encouraging 
successes in applications of nsPEF for the treatment of cancer. In vitro, pulse power ablation 
induces cell death through multiple mechanisms that appear to be cell type-dependent. As 
discussed above, effects are evident on the plasma membrane, endoplasmic reticulum, 
cytoskeletal structure, mitochondria and nucleus. Coincident with cell death are events that 
are dependent and independent of calcium, caspases and cytochrome c release depending 
on the cell type. In murine B16f10 melanoma in vitro, nsPEFs induce caspase activation 
without cytochrome c release and with limited effects on phosphatidylserine externalization. 
The first studies demonstrating the possibility that nsPEFs could kill cancer cells used a 
B10.2 fibrosarcoma tumor in mice [Beebe et al., 2002, 2003b, 2004]. These studies used the 
first developed electrode design for in vivo applications of pulse power to tumors. Since then 
significant advances with a number of electrode designs have been used [Beebe et al., 2010; 
Kolb et al., 2009; Garon et al., 2007; Nuccitelli et al., 2006, 2010]. The fibrosarcoma studies 
followed studies showing that pulse power with nanosecond pulsed electric fields induced 
markers for apoptosis in Jurkat and HL-60 cells [Beebe et al., 2002]. In initial fibrosarcoma 
tumor studies, nsPEFs reduced tumor size in vivo, induced activation of caspase catalytic 
activity and demonstrated the presence of TUNEL positive cells when tumors were treated 
ex vivo [Beebe et al., 2003b, 2004]. Since then, nsPEFs were shown to eliminate B16f10 
melanoma tumors in vivo without recurrence using two different electrode designs 
[Nuccitelli et al., 2006, 2009]. These studies demonstrated calcium mobilization and 
confirmed the possibility for DNA damage using the comet assay in B16f10 cells in vitro and 
decreased microvascular density using CD34 as a marker in vivo. Chen et al. [2010] revealed 
apoptosis initiation using active caspase-specific antibodies and the expression of TUNEL 
positive cells confirming DNA damage in vivo. In addition, this study also showed that 
nsPEFs could induce DNA double strand breaks using antibodies specific for 
phosphorylated Histone 2AX, an early and sensitive marker for this trait [Bonner et al., 
2008]. These DNA damage and DNA double strand break markers peaked before caspases 
were fully active, suggesting that they might not be due to apoptosis. This study also 
indicated that nsPEFs may be responsible for anti-angiogenesis mechanisms showing 
decreases in vascular endothelial cell growth factor (VEGF), which is required for the 
angiogenic switch, a limiting factor for multistage carcinogenesis [Hanahan and Weinberg, 
2000, 2011] and platelet derived endothelial growth factor (PD-ECGF). Decreases in several 
microvascular density factors, including CD-31, CD-34 and CD-105, were also 
demonstrated. CD-31 (PECAM-1), a platelet-endothelial cell adhesion molecule used as a 
pan-endothelial cell marker, and CD-34, an endothelial cell marker, were decreased by 65-
70%. CD-105 (endoglin) was decreased >40%. CD-105, which is part of the TGFǃ receptor 
complex, is an important angiogenic factor that is strongly expressed in tumors and is an 
independent prognostic indicator, wherein increased MVD correlates with shorter survival 
[Duff et al., 2003]. 
The results indicate that pulse power ablation target two of the seven common cancer 
hallmarks (Hanahan and Weinberg, 2000, 2011; Kroemer and Pouyssegur 2008) on solid 
B16f10 melanoma tumors, including apoptosis evasion and sustained angiogenesis. The 
latter is critical for a third hallmark, invasion and metastasis. The study concluded that 
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apoptosis was initiated but most likely did not go to completion as suggested by the absence 
of DNA fragmentation ladders but the presence of large molecular weight DNA fragments 
on agarose gels [Chen et al., 2010]. It was suggested that the initiation of apoptosis without 
completion was likely due to loss of vascular viability contributing to infarctive tumor 
death. However, the presence of active caspases for several hours after nsPEF treatment 
could help disassemble tumors to initiate the removal of dead tumor cells. Consequently, 
nsPEF ablation induces B16f10 tumor elimination by multiple mechanisms that can bypass 
common cancer mutations that frequently result in chemotherapeutic resistances and 
metastasis. The application of nsPEF ablation is safe, has no systemic side effects, is non- or 
minimally invasive, leaves no scars, and provides an inexpensive and effective method to 
the arsenal for cancer treatment strategies [Chen et al., 2010; Nuccitelli et al., 2006, 2009, 
2010]  
13. Advantages for nsPEF ablation as a cancer therapy 
There are a number of advantages for using nsPEF ablation as a means for cancer therapy as 
opposed to other physical methods that rely on overt necrosis for tumor cell death. These 
advantages include (1) targeting multiple programmed cell death mechanisms including 
apoptosis induction and anti-angiogenesis, two well known cancer hallmarks, the latter 
necessary for a third cancer hallmark, invasion and metastasis; (2) targeting rapid death 
induction with minimal treatment exposures, which reduces chances for resistances and 
recurrences; (3) targeting non-mitochondria-mediated programmed cell death in melanoma, 
which can bypass many melanoma and other cancer-causing mutations; (4) an apparent 
broad specificity for cell death induction, effective for all cells within electric fields, 
including rapidly growing tumor cells, slower growing host cells that have been hijacked by 
tumors and cancer stem cells, all constituting the tumor mass and the microenvironment; (5) 
small vessel, local infarction, which deprives tumors of feeder vessels that are important for 
immediate oxygenation and nutrition, which provides local stresses; (6) minimal local and 
systemic side effects and (7) the potential for enhancing immune surveillance from cells 
undergoing apoptotic. 
NsPEF ablation provides a local targeted treatment at the level of the entire tumor without 
systemic effects, affecting multiple molecular structures and functions in plasma membranes 
and intracellular organelles. All tumor cells exposed to conditions of pulse duration, 
number and electric field that are above the threshold for cell death are subject to 
programmed and other forms of cell death. The foremost targets bypass two important 
hallmarks of cancer causing apoptosis-like appearances and anti-angiogenesis. In its full 
capacity, this should lead to inhibition of invasion and metastasis, another cancer hallmark. 
The multi-mechanisms for nsPEF interactions with tumors are similar to using a 
combination of at least two chemotherapeutic agents and/or molecular targeted drugs that 
induce apoptosis-like characteristics and limit angiogenesis; both well defined sites for 
cancer targeted drugs. The observed decreases in vessel numbers and angiogenic factors 
(VEGF and PD-ECGF) prevent the possibility for re-vascularization and reduce chances for 
tumor cells to continue to proliferate [Chen et al., 2010]. Sustained hypoxia has been 
implicated in metastasis and hypoxia induced factor (HIF) transcriptional activity that is 
beyond that of normal tissue [Cairns et al., 2001; Peng et al., 2006]. The combination of 
apoptosis-like qualities and anti-angiogenesis as sites of nsPEF action makes this an 
attractive cancer therapeutic modality [Chen et al., 2010]. 
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Another advantage to nsPEF interactions with tumors is the rapid onset of apoptosis-like 
features and some level of tumor infarction. Caspase activation in vitro is seen within 30-45 
minutes [Beebe et al., 2002, 2003a] and within the first hours after treatment in vivo [Chen et 
al., 2010]. This rapid caspase activation is likely to rapidly induce cell death mechanisms. In 
contrast, chemotherapeutic agents, ionizing radiation and molecular targeting drugs are 
administered over weeks or months and often do not eliminate cancer but reduce tumor size 
or stabilize it. This provides a potential for mechanisms to allow tumor cells to escape 
therapeutic action and increases the possibility for treatment resistances and recurrences. 
Examples include upregulation of drug efflux transporters and tumor immune evasion in 
chemoresistant melanomas [Schatton et al., 2009] and the chemotherapy-induced 
upregulation of factors like clusterin, an anti-apoptotic protein conferring resistances to 
several cell death agonists [Wei et al., 2009]. As indicated earlier, two mechanisms of 
resistance to PLX4220 treated melanoma tumors include creating alternative survival 
pathways by overexpressing a cell surface Beta-type protein platelet derived growth factor 
receptor or by reactivating the normal BRAF survival pathway [Nazarian et al., 2010]. Ultra-
high pulse power-induced interruption of the tumor small vessel blood supply is also rapid, 
limiting blood flow to the tumor as it is being dismantled, at least in part by apoptosis-like 
mechanisms. NsPEF ablation has rapid therapeutic onset, which should reduce the potential 
for resistances and recurrences as all tumor cells are affected by conditions above the 
threshold for cell death.  
Many mutations that lead to cancers often occur in mitochondria-mediated mechanisms and 
pathways, most likely because there are more regulatory sites through intrinsic and Bid-
dependent extrinsic pathways than in mitochondria-independent apoptosis pathways 
[Hanahan and Weinberg, 2011]. Consequently, many chemotherapeutic agents and ionizing 
radiation have significant effects on mitochondria-dependent apoptotic mechanisms [Latai, 
2008]. NsPEF ablation has both mitochondria-dependent and -independent sites of action 
that appear to be cell type-dependent. In melanoma, the apparent exclusive recruitment of 
cytochrome c-independent extrinsic mechanisms provides an alternative mechanism to 
many cancer therapeutic treatments that act on mitochondria-dependent pathways. A 
simple, bistable rate-equation-based model of apoptosis pathways predicted that the 
extrinsic caspase-8 mechanism was more sensitive than the mitochondrial intrinsic pathway 
for electric pulse induced cell apoptosis [Song et al., 2010], which is in keeping with results 
from B16F10 melanoma studies [Ford et al., 2010] as well as HCT116 colon carcinoma [Hall 
et al., 2007a] and E4 squamous cell carcinoma studies [Ren and Beebe, 2011]. Thus, by 
favoring the extrinsic apoptosis pathway, nsPEFs may bypass many cancer causing 
mutations in mitochondria-mediated apoptosis mechanisms, which are often involved in 
resistances and recurrences.  
Another potential advantage of nsPEF ablation for cancer therapy is related to 
considerations for cell type specificity. Chemotherapeutic drugs and ionizing radiation 
primarily affect rapidly dividing cells. Effects of nsPEFs appear to be cell-type specific for a 
number of cell responses suggesting some cell type specificity; however, it remains to be 
determine if this has therapeutic relevance. Cultured cells that grow attached as opposed to 
cells in suspension require longer pulse durations, greater numbers and/or higher electric 
fields to elicit cell responses [Stacey et al., 2003], including cell death [Beebe et al., 2002; Hall 
et al., 2007a]. In contrast to conventional electroporation, which affects larger cells more 
readily than smaller ones, cell size did not matter for plasma membrane permeabilization 
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with nsPEF ablation [Hair et al., 2003]. However, there is no evidence that nsPEF ablation 
preferentially affect only rapidly proliferating cells. S phase synchronized cells under 
limiting pulse power conditions exhibited greater membrane integrity and maintained 
cytoskeletal structure but did not differ in survival compared to unsynchronized cells [Hall 
et al., 2007b]. Thus, within a heterogeneous tumor mass, nsPEF therapy is expected to 
induce cell death in rapidly proliferating tumor cells as well as slower proliferating host 
cells that are collaborating with tumor cells regardless of their size. This suggests an 
alternative to almany therapeutic regiments that predominantly target rapid proliferating 
cells. Melanoma tumors also can contain cancer stem cells or other slower cycling cells, 
which possess characteristics common to normal stem cells, including self renewal capacity, 
high tumorigenicity and potential to differentiate into multiple cell types [Fang et al., 2005; 
Grichnik et al., 2006; Roesch et al., 2010; Zabierowski and Herlyn; 2008a, b]. Cancer stem 
cells or other slower cycling cells may be more prevalent in tumors than initially considered 
as demonstrated with melanomas from 12 different patients [Quintana et al., 2008]. Herlyn 
and colleagues have suggested an alternative to the unidirectional stem cell model in 
melanoma proposing a dynamic temporarily distinct subpopulation of slow cycling 
melanoma cells that are responsible for tumor maintenance [Roesch et al., 2010]. The 
existence of these slow cycling cells is clinically relevant because they would be less resistant 
to most therapeutic regimens; however, they would probably not be resistant to nsPEF 
ablation. Cancer stem cells or slow cycling cells have been reported to be responsible for 
recurrences after chemotherapy and ionizing radiation therapy through multiple 
mechanisms [Weissman and Clarke, 2009]. One of these mechanisms is to minimize therapy-
induced DNA damage that is produced by free radical scavengers to minimize the effects of 
reactive oxygen species (ROS). Cancer stem cells had significantly lower levels of ROS and 
enhanced ROS defenses compared to non-tumorigenic cells [Diehn et al., 2009]. NsPEF 
ablation is non-ionizing and it does not appear to induce cell death by generating 
measurable ROS in B16F10 melanoma cells [Ford et al., 2010] or in E4 squamous cell 
carcinoma [Ren and Beebe, 2011]. Thus, this mechanism would not provide survival 
advantages to cancer stem cells exposed to nsPEF ablation. Another mechanism that may be 
responsible for resistance and recurrences with conventional treatments is to preferentially 
activate DNA damage checkpoint response and increases in DNA repair capacity [Bao et al., 
2006]. NsPEF ablation does cause DNA damage in B16F10 melanoma cells [Nuccitelli et al., 
2009] and tumors [Chen et al., 2010]. However, DNA damage may not be a major cause of 
cell death in these tumors. Furthermore, DNA damage induces apoptosis through release of 
pro-apoptotic factors from mitochondria [Gross et al., 1999; Hengartner et al., 2000; 
Korsmeyer et al., 2000] and nsPEF ablation induces melanoma cell death with minimal 
release of pro-apoptotic factors [Figure 3; Ford et al., 2010]. Thus, minimizing DNA damage 
and enhancing repair would not provide survival advantages to cancer stem cells or slow 
cycling cells exposed to nsPEF ablation. 
An early study investigating local tissue affects at tumor treatment sites indicated that blood 
flow to the tumor was disrupted as blood cell leaked out of the tumor around small vessels 
[Nuccitelli et al., 2006]. This local tumor infarction with an absence of local blood flow for 
about two weeks appears to be sufficient to deprive tumors of needed oxygenation and 
nutrition to facilitate tumor demise. A subsequent analysis also demonstrated the presence 
of iron stain suggesting nsPEF caused slight hemorrhage in the treated tissue [Chen et al., 
2010]. Other studies demonstrated that microvessel density markers were significantly 
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reduced, indicating that angiogenesis and/or vasculogenesis were significantly thwarted 
[Chen et al., 2010; Nuccitelli et al., 2009]. 
An important benefit to local treatment with nsPEFs is an absence of chemical side effects 
and toxicities, which are common with nearly all systemic treatments, especially 
chemotherapy and ionizing radiation. In studies with mice, nsPEF ablation has minimal and 
resolvable effects on skin. With parallel plate electrodes that eliminated B16F10 melanoma, 
the stratum corneum showed signs of necrosis and hemorrhage with accompanying 
superficial erosion of the epidermis [Nuccitelli et al., 2006]. However, these characteristics 
appeared two days after treatment, differentiating the effect from burn or heat related 
injuries, which occur immediately. With a four plus one needle array electrode, nsPEF 
ablation caused some edema and bleeding, but the damage was resolved within a week 
[Chen et al., 2009]. Small scabs formed but were resolved within two weeks and did not 
leave a scar. However, mice do not readily scar. In an unpublished clinical study observing 
effects of nsPEFs on human skin, treatments with two parallel needle electrodes caused 
some irritation, redness and itching at insertion / treatment sites, which were readily 
relieved by anti-histamines, local anti-inflammatory ointment and protection from 
scratching. The treatments caused no permanent scars or discoloration of skin regardless of 
pigmentation. While there was some pain and discomfort with applications of nsPEF 
without anesthesia, they were eliminated when a local anesthetic was injected at treatment 
sites. In addition, application of nsPEFs resulted in few/no muscle contractions, when 
applied appropriately, which are common with conventional electroporation and 
irreversible electroporation. In addition, studies monitoring general reactions to nsPEF 
ablation with parallel plate electrodes, mice had slightly higher heart rates and respiratory 
rates, but body temperature and systolic blood pressure did not change significantly [Chen 
et al., 2009]. Thus, as tested so far, applications of nsPEF ablation are generally safe, non-
toxic and without scarring or other permanent effects on skin in mice and humans. While 
pulse power treatments can now be used for surface tumors using needle or plate 
electrodes, applications to internal tumors will likely be possible as catheter electrodes are 
developed for laparoscopic surgeries. For all nsPEF treatments, multi-needle electrode 
systems with adjustable field orientations would likely enhance apoptosis in the context of 
pulsed voltage-induced inactivation of tumor cells [Song et al., 2010]. 
An ending argument for applications of nsPEF ablation involves a significant question for 
the treatment of melanoma and other cancers: Can pulse power ablation with nsPEF 
effectively treat metastatic melanoma as a systemic disease? This question has begun to be 
addressed in an experimental protocol, not with B16f10 melanoma cells, but with Hepa 1-6 
hepatocellular carcinoma (HCC) cells [Chen and Beebe, unpublished]. When Hepa 1-6 
tumors were treated with 900 pulses at 100ns and 55kV/cm, tumors were eliminated in 6 of 
the 8 mice, while all control mice were humanely euthanized due to tumor burden 14-18 
days after tumor initiated. When the 6 successfully treated mice were tumor free for 60 days, 
tumors cells were injected in the opposite flank as before. None of these animals grew 
tumors for 49 days before the experiment was terminated. In naïve age-match control HCC 
tumors grew to treatable sizes in less than two weeks. These results suggest that nsPEF 
ablation allows a host cell immune response. While these studies must be repeated and the 
mechanisms of this resistance further investigated, these results suggest that nsPEF ablation 
addresses another cancer hallmark, evasion of immune surveillance. 
It is generally accepted that an ultimate outcome of apoptosis is the removal of aberrant cells 
without inflammation. This is certainly true for during development and the clearance of 
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immune cells, but it is likely not completely true for cancer therapeutic agents that induce 
apoptosis in tumors. The tumor masses are likely not cleared before some tumor cells are 
functionally dead. Many chemotherapeutic agents, as well as nsPEF ablation, induce cell 
death by apoptosis. However, it is generally considered, but not universally, that apoptosis 
is immunologically silent. Most chemotherapeutic agents, many of which induce apoptosis, 
are immunosuppressive. Conversely, considering the challenge experiments of HCC tumors 
presented above, nsPEF ablation may not be immunologically silent or immunosuppressive. 
Thus, it is possible for immune cells to present antigens from apoptotic cells. Alberts et al., 
[1998] demonstrated that human dendritic cells efficiently present antigen derived from 
apoptotic cells that stimulated class I-restricted CD8+ cytotoxic T-cells. When Chattergoon 
and co-workers [2000] engineered Fas-mediated apoptotic death of antigen-bearing cells in 
vivo by co-expressing the immunogen and Fas in the same cells, they observed that the 
death of antigen-bearing cells resulted in increased antigen acquisition by antigen 
presenting cells including dendritic cells (DCs). Casares et al., [2005] demonstrated that 
caspase inhibition did not inhibit doxorubicin (DX)-induced cell death, yet suppressed the 
immunogenicity of dying tumor cells in several rodent models of neoplasia. Further, 
depletion of DCs or CD8+T cells abolished the immune response against DX-treated 
apoptotic tumor cells in vivo. Russo et al., [2000] showed that irradiated vector-producing 
cells undergoing apoptosis were phagocytosed by dendritic cells (DCs). They then took 
lymphocytes obtained from a patient affected by a MAGE-3(+) melanoma, stimulated them 
in vitro with autologous DCs previously exposed to irradiated MAGE-3-expressing cells, 
which led to induction of MAGE-3-specific cytotoxic effectors, directed against a yet 
unknown MAGE-3 epitope. These results indicate not only that apoptotic cells and perhaps 
the presence of active caspases can be immunogenic, it is suggested that they may have 
immunogenicity. Finally, these results not only indicate that apoptotic cells can stimulate 
anti-neoplastic immune responses, but that they could generate cancer vaccines, having 
important implication for gene therapy for melanoma and other cancers.  
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